Consequently, it can be inferred that emodin’s inhibitory effect on TNF-α activity is primarily due to its stabilization of the TNF-α asymmetric trimer, which potentially disrupts the full activation of downstream inflammatory signaling pathways, presenting a novel approach to managing RA distinct from traditional therapies that broadly neutralize TNF-α activity. Here, TNF is linked to rheumatoid arthritis.